Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells
- PMID: 15520166
- DOI: 10.1158/0008-5472.CAN-04-2550
Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells
Abstract
Nucleic acid ligands (aptamers) are potentially well suited for the therapeutic targeting of drug encapsulated controlled release polymer particles in a cell- or tissue-specific manner. We synthesized a bioconjugate composed of controlled release polymer nanoparticles and aptamers and examined its efficacy for targeted delivery to prostate cancer cells. Specifically, we synthesized poly(lactic acid)-block-polyethylene glycol (PEG) copolymer with a terminal carboxylic acid functional group (PLA-PEG-COOH), and encapsulated rhodamine-labeled dextran (as a model drug) within PLA-PEG-COOH nanoparticles. These nanoparticles have the following desirable characteristics: (a) negative surface charge (-50 +/- 3 mV, mean +/- SD, n = 3), which may minimize nonspecific interaction with the negatively charged nucleic acid aptamers; (b) carboxylic acid groups on the particle surface for potential modification and covalent conjugation to amine-modified aptamers; and (c) presence of PEG on particle surface, which enhances circulating half-life while contributing to decreased uptake in nontargeted cells. Next, we generated nanoparticle-aptamer bioconjugates with RNA aptamers that bind to the prostate-specific membrane antigen, a well-known prostate cancer tumor marker that is overexpressed on prostate acinar epithelial cells. We demonstrated that these bioconjugates can efficiently target and get taken up by the prostate LNCaP epithelial cells, which express the prostate-specific membrane antigen protein (77-fold increase in binding versus control, n = 150 cells per group). In contrast to LNCaP cells, the uptake of these particles is not enhanced in cells that do not express the prostate-specific membrane antigen protein. To our knowledge, this represents the first report of targeted drug delivery with nanoparticle-aptamer bioconjugates.
Similar articles
-
Plumbagin-loaded aptamer-targeted poly D,L-lactic-co-glycolic acid-b-polyethylene glycol nanoparticles for prostate cancer therapy.Medicine (Baltimore). 2017 Jul;96(30):e7405. doi: 10.1097/MD.0000000000007405. Medicine (Baltimore). 2017. PMID: 28746182 Free PMC article.
-
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo.Proc Natl Acad Sci U S A. 2006 Apr 18;103(16):6315-20. doi: 10.1073/pnas.0601755103. Epub 2006 Apr 10. Proc Natl Acad Sci U S A. 2006. PMID: 16606824 Free PMC article.
-
Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles.Proc Natl Acad Sci U S A. 2008 Nov 11;105(45):17356-61. doi: 10.1073/pnas.0809154105. Epub 2008 Oct 31. Proc Natl Acad Sci U S A. 2008. PMID: 18978032 Free PMC article.
-
Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review.Eur J Pharm Biopharm. 2013 Nov;85(3 Pt A):427-43. doi: 10.1016/j.ejpb.2013.07.002. Epub 2013 Jul 17. Eur J Pharm Biopharm. 2013. PMID: 23872180 Review.
-
Thermally cross-linked superparamagnetic iron oxide nanoparticle-A10 RNA aptamer-doxorubicin conjugate.2008 Aug 29 [updated 2008 Oct 8]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. 2008 Aug 29 [updated 2008 Oct 8]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 20641568 Free Books & Documents. Review.
Cited by
-
New insights into targeted therapy of glioblastoma using smart nanoparticles.Cancer Cell Int. 2024 May 7;24(1):160. doi: 10.1186/s12935-024-03331-3. Cancer Cell Int. 2024. PMID: 38715021 Free PMC article. Review.
-
Aptamers for the Delivery of Plant-Based Compounds: A Review.Pharmaceutics. 2024 Apr 14;16(4):541. doi: 10.3390/pharmaceutics16040541. Pharmaceutics. 2024. PMID: 38675202 Free PMC article. Review.
-
Astrocyte-targeted siRNA delivery by adenosine-functionalized LNP in mouse TBI model.Mol Ther Nucleic Acids. 2023 Oct 20;34:102065. doi: 10.1016/j.omtn.2023.102065. eCollection 2023 Dec 12. Mol Ther Nucleic Acids. 2023. PMID: 38028196 Free PMC article.
-
New Pathway for Cisplatin Prodrug to Utilize Metabolic Substrate Preference to Overcome Cancer Intrinsic Resistance.ACS Cent Sci. 2023 Jul 12;9(7):1297-1312. doi: 10.1021/acscentsci.3c00286. eCollection 2023 Jul 26. ACS Cent Sci. 2023. PMID: 37521786 Free PMC article.
-
Synthesis and Optimization of the Docetaxel-Loaded and Durvalumab-Targeted Human Serum Albumin Nanoparticles, In Vitro Characterization on Triple-Negative Breast Cancer Cells.ACS Omega. 2023 Jul 13;8(29):26287-26300. doi: 10.1021/acsomega.3c02682. eCollection 2023 Jul 25. ACS Omega. 2023. PMID: 37521641 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous